HRP20151060T1 - 4-aril-n-fenil-1,3,5-triazin-2-amini koji sadrže sulfoksimin skupinu - Google Patents
4-aril-n-fenil-1,3,5-triazin-2-amini koji sadrže sulfoksimin skupinu Download PDFInfo
- Publication number
- HRP20151060T1 HRP20151060T1 HRP20151060TT HRP20151060T HRP20151060T1 HR P20151060 T1 HRP20151060 T1 HR P20151060T1 HR P20151060T T HRP20151060T T HR P20151060TT HR P20151060 T HRP20151060 T HR P20151060T HR P20151060 T1 HRP20151060 T1 HR P20151060T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- methyl
- triazin
- rac
- fluoro
- Prior art date
Links
- 125000005555 sulfoximide group Chemical group 0.000 title 1
- -1 halo-C1-C3-alkyl- Chemical group 0.000 claims 133
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 43
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 25
- 125000001424 substituent group Chemical group 0.000 claims 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 229910052731 fluorine Inorganic materials 0.000 claims 17
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 16
- 125000001153 fluoro group Chemical group F* 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 14
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 229910052801 chlorine Inorganic materials 0.000 claims 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- HSODISFNJMBQLW-UHFFFAOYSA-N 4-(2,3-dihydro-1-benzofuran-7-yl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C=3OCCC=3C=CC=2)=C1 HSODISFNJMBQLW-UHFFFAOYSA-N 0.000 claims 3
- WKMLBAKTAZIKEE-UHFFFAOYSA-N 4-(2-methoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound COC1=CC=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 WKMLBAKTAZIKEE-UHFFFAOYSA-N 0.000 claims 3
- ILVMBMOIUKZZRA-UHFFFAOYSA-N 4-(3,4-dihydro-2h-chromen-8-yl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C=3OCCCC=3C=CC=2)=C1 ILVMBMOIUKZZRA-UHFFFAOYSA-N 0.000 claims 3
- DLZIASJRLRECRS-UHFFFAOYSA-N 4-(4-fluoro-2-methoxyphenyl)-n-[3-fluoro-5-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=C(F)C=2)=N1 DLZIASJRLRECRS-UHFFFAOYSA-N 0.000 claims 3
- KEAPAIZOLSVRNZ-UHFFFAOYSA-N 4-(4-fluoro-2-phenylmethoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=CC=CC=2)=C1 KEAPAIZOLSVRNZ-UHFFFAOYSA-N 0.000 claims 3
- VNQSADCYOBYZMX-UHFFFAOYSA-N 4-(4-fluoro-2-prop-2-ynoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC#C)=C1 VNQSADCYOBYZMX-UHFFFAOYSA-N 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- YXCJYVQJSBEOPI-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C=3OCCOC=3C=CC=2)=C1 YXCJYVQJSBEOPI-UHFFFAOYSA-N 0.000 claims 2
- GPGQUICOSOWSJF-UHFFFAOYSA-N 4-(2-but-2-ynoxy-4-fluorophenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CC#CCOC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 GPGQUICOSOWSJF-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- ISLASAXDUXLSON-UHFFFAOYSA-N 2-[[5-fluoro-2-[4-[3-[(methylsulfonimidoyl)methyl]anilino]-1,3,5-triazin-2-yl]phenoxy]methyl]prop-2-en-1-ol Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC(=C)CO)=C1 ISLASAXDUXLSON-UHFFFAOYSA-N 0.000 claims 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- KBOXUYIQIFCQGQ-UHFFFAOYSA-N 3-[[5-fluoro-2-[4-[3-[(methylsulfonimidoyl)methyl]anilino]-1,3,5-triazin-2-yl]phenoxy]methyl]benzonitrile Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=C(C=CC=2)C#N)=C1 KBOXUYIQIFCQGQ-UHFFFAOYSA-N 0.000 claims 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- XKDLBLCFRZLVPS-UHFFFAOYSA-N 4-(2-ethoxy-4-fluorophenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CCOC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 XKDLBLCFRZLVPS-UHFFFAOYSA-N 0.000 claims 1
- AAEDIJKSTQIMCS-UHFFFAOYSA-N 4-(4,5-difluoro-2-methoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=C(F)C=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 AAEDIJKSTQIMCS-UHFFFAOYSA-N 0.000 claims 1
- TWAUMQLBNMVMLO-UHFFFAOYSA-N 4-(4-chloro-2-methoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound COC1=CC(Cl)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 TWAUMQLBNMVMLO-UHFFFAOYSA-N 0.000 claims 1
- ACWKGTGIJRCOOM-UHFFFAOYSA-N 4-(4-fluoro-2-methoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 ACWKGTGIJRCOOM-UHFFFAOYSA-N 0.000 claims 1
- JINMVIWLGGPUOE-UHFFFAOYSA-N 4-(4-fluoro-2-methoxyphenyl)-n-[3-[(oxan-4-ylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(=N)(=O)C3CCOCC3)C=CC=2)=N1 JINMVIWLGGPUOE-UHFFFAOYSA-N 0.000 claims 1
- NLCBKVLTHACFFE-UHFFFAOYSA-N 4-(4-fluoro-2-prop-2-enoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=C)=C1 NLCBKVLTHACFFE-UHFFFAOYSA-N 0.000 claims 1
- KSCZIASPGQACKX-UHFFFAOYSA-N 4-(4-fluoro-2-propoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CCCOC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 KSCZIASPGQACKX-UHFFFAOYSA-N 0.000 claims 1
- UTZPONOYNCWWSY-UHFFFAOYSA-N 4-[2-(1-cyclopentylethoxy)-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound C1CCCC1C(C)OC1=CC(F)=CC=C1C(N=1)=NC=NC=1NC1=CC=CC(CS(C)(=N)=O)=C1 UTZPONOYNCWWSY-UHFFFAOYSA-N 0.000 claims 1
- VYFFHUCKQLXQET-UHFFFAOYSA-N 4-[2-(2,2-difluoroethoxy)-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC(F)F)=C1 VYFFHUCKQLXQET-UHFFFAOYSA-N 0.000 claims 1
- UQLQRSRVCDLTRN-UHFFFAOYSA-N 4-[2-(2-cyclopropylethoxy)-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCCC2CC2)=C1 UQLQRSRVCDLTRN-UHFFFAOYSA-N 0.000 claims 1
- CPKDZRYUNSDUDC-UHFFFAOYSA-N 4-[2-(cyclohexylmethoxy)-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC2CCCCC2)=C1 CPKDZRYUNSDUDC-UHFFFAOYSA-N 0.000 claims 1
- YZYIXCCNLDPFSY-UHFFFAOYSA-N 4-[2-[(3,4-dichlorophenyl)methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC=CC=2)OCC=2C=C(Cl)C(Cl)=CC=2)=C1 YZYIXCCNLDPFSY-UHFFFAOYSA-N 0.000 claims 1
- AYNIVSXDBPZHKI-UHFFFAOYSA-N 4-[2-[(3-chloro-4-fluorophenyl)methoxy]-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=C(Cl)C(F)=CC=2)=C1 AYNIVSXDBPZHKI-UHFFFAOYSA-N 0.000 claims 1
- ODQNZRXLNIAATG-UHFFFAOYSA-N 4-[2-[(3-chloro-5-fluorophenyl)methoxy]-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=C(Cl)C=C(F)C=2)=C1 ODQNZRXLNIAATG-UHFFFAOYSA-N 0.000 claims 1
- VVWVTEUZCVNOIF-UHFFFAOYSA-N 4-[2-[(3-chlorophenyl)methoxy]-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=C(Cl)C=CC=2)=C1 VVWVTEUZCVNOIF-UHFFFAOYSA-N 0.000 claims 1
- XAGZPNDRCQGPAH-UHFFFAOYSA-N 4-[2-[(4-chlorophenyl)methoxy]-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=CC(Cl)=CC=2)=C1 XAGZPNDRCQGPAH-UHFFFAOYSA-N 0.000 claims 1
- LOBYSFZFNMZNHN-UHFFFAOYSA-N 4-[2-[(4-fluorophenyl)methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC=CC=2)OCC=2C=CC(F)=CC=2)=C1 LOBYSFZFNMZNHN-UHFFFAOYSA-N 0.000 claims 1
- KDWXTPDMELXCLF-ARJAWSKDSA-N 4-[2-[(z)-but-2-enoxy]-4-fluorophenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound C\C=C/COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 KDWXTPDMELXCLF-ARJAWSKDSA-N 0.000 claims 1
- KEAPAIZOLSVRNZ-UPEJGULISA-N 4-[2-[dideuterio-(2,3,4,5,6-pentadeuteriophenyl)methoxy]-4-fluorophenyl]-N-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound [2H]C1=C([2H])C([2H])=C(C([2H])=C1[2H])C([2H])([2H])OC1=CC(F)=CC=C1C1=NC(NC2=CC=CC(CS(C)(=N)=O)=C2)=NC=N1 KEAPAIZOLSVRNZ-UPEJGULISA-N 0.000 claims 1
- AXLURCFSKIWPCA-UHFFFAOYSA-N 4-[4-fluoro-2-(1,2-oxazol-3-ylmethoxy)phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC2=NOC=C2)=C1 AXLURCFSKIWPCA-UHFFFAOYSA-N 0.000 claims 1
- PBWKVTQEEJYCRC-UHFFFAOYSA-N 4-[4-fluoro-2-(1,3-thiazol-5-ylmethoxy)phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2SC=NC=2)=C1 PBWKVTQEEJYCRC-UHFFFAOYSA-N 0.000 claims 1
- GXPLQWLEZXXOPK-UHFFFAOYSA-N 4-[4-fluoro-2-(2-methylprop-2-enoxy)phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CC(=C)COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 GXPLQWLEZXXOPK-UHFFFAOYSA-N 0.000 claims 1
- DBAYHNCGOFKFSU-UHFFFAOYSA-N 4-[4-fluoro-2-(pyridin-2-ylmethoxy)phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2N=CC=CC=2)=C1 DBAYHNCGOFKFSU-UHFFFAOYSA-N 0.000 claims 1
- PCURPHBYHAOEHD-UHFFFAOYSA-N 4-[4-fluoro-2-(pyridin-3-ylmethoxy)phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=NC=CC=2)=C1 PCURPHBYHAOEHD-UHFFFAOYSA-N 0.000 claims 1
- JSSJHBWAMPCAOA-UHFFFAOYSA-N 4-[4-fluoro-2-(pyridin-4-ylmethoxy)phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=CN=CC=2)=C1 JSSJHBWAMPCAOA-UHFFFAOYSA-N 0.000 claims 1
- UOOJOAMMYFVKID-UHFFFAOYSA-N 4-[4-fluoro-2-[(2,3,5-trifluorophenyl)methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C(=C(F)C=C(F)C=2)F)=C1 UOOJOAMMYFVKID-UHFFFAOYSA-N 0.000 claims 1
- SFVFBKQDFKQOSH-UHFFFAOYSA-N 4-[4-fluoro-2-[(2,4,5-trifluorophenyl)methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C(=CC(F)=C(F)C=2)F)=C1 SFVFBKQDFKQOSH-UHFFFAOYSA-N 0.000 claims 1
- RQFBVVFCXVOINX-UHFFFAOYSA-N 4-[4-fluoro-2-[(2-fluoropyridin-4-yl)methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=C(F)N=CC=2)=C1 RQFBVVFCXVOINX-UHFFFAOYSA-N 0.000 claims 1
- NBZSIYZKQIXZPP-UHFFFAOYSA-N 4-[4-fluoro-2-[(3,4,5-trifluorophenyl)methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=C(F)C(F)=C(F)C=2)=C1 NBZSIYZKQIXZPP-UHFFFAOYSA-N 0.000 claims 1
- XCHXFUWJBRPMQZ-UHFFFAOYSA-N 4-[4-fluoro-2-[(4-fluoro-3-methylphenyl)methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound C1=C(F)C(C)=CC(COC=2C(=CC=C(F)C=2)C=2N=C(NC=3C=C(CS(C)(=N)=O)C=CC=3)N=CN=2)=C1 XCHXFUWJBRPMQZ-UHFFFAOYSA-N 0.000 claims 1
- VNHDYKMEDVFEBK-UHFFFAOYSA-N 4-[4-fluoro-2-[1-(4-fluorophenyl)ethoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound C=1C=C(F)C=CC=1C(C)OC1=CC(F)=CC=C1C(N=1)=NC=NC=1NC1=CC=CC(CS(C)(=N)=O)=C1 VNHDYKMEDVFEBK-UHFFFAOYSA-N 0.000 claims 1
- YHLYDKKDZLWEJG-UHFFFAOYSA-N 4-[4-fluoro-2-[2-(oxan-4-yl)ethoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCCC2CCOCC2)=C1 YHLYDKKDZLWEJG-UHFFFAOYSA-N 0.000 claims 1
- YYRGTROMMSPUAJ-UHFFFAOYSA-N 4-[4-fluoro-2-[[3-fluoro-5-(trifluoromethyl)phenyl]methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=C(C=C(F)C=2)C(F)(F)F)=C1 YYRGTROMMSPUAJ-UHFFFAOYSA-N 0.000 claims 1
- NMVJKGNENUYVOE-UHFFFAOYSA-N 4-[4-fluoro-2-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound CS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OCC=2C=CC(=CC=2)C(F)(F)F)=C1 NMVJKGNENUYVOE-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- ZDPKSWDQOHZKLC-UHFFFAOYSA-N N-[3-[(ethylsulfonimidoyl)methyl]phenyl]-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine Chemical compound CCS(=N)(=O)Cc1cccc(Nc2ncnc(n2)-c2ccc(F)cc2OC)c1.CCS(=N)(=O)Cc1cccc(Nc2ncnc(n2)-c2ccc(F)cc2OC)c1 ZDPKSWDQOHZKLC-UHFFFAOYSA-N 0.000 claims 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- AARZZTJKBYIKBZ-UHFFFAOYSA-N n-[3,4-difluoro-5-[(methylsulfonimidoyl)methyl]phenyl]-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C(F)=C(F)C=2)=N1 AARZZTJKBYIKBZ-UHFFFAOYSA-N 0.000 claims 1
- AQRMHECVRYEXOP-UHFFFAOYSA-N n-[3-[(ethylsulfonimidoyl)methyl]phenyl]-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine Chemical compound CCS(=N)(=O)CC1=CC=CC(NC=2N=C(N=CN=2)C=2C(=CC(F)=CC=2)OC)=C1 AQRMHECVRYEXOP-UHFFFAOYSA-N 0.000 claims 1
- OWPCQFQPJGAQSP-UHFFFAOYSA-N n-[3-[(n,s-dimethylsulfonimidoyl)methyl]phenyl]-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=O)=NC)C=CC=2)=N1 OWPCQFQPJGAQSP-UHFFFAOYSA-N 0.000 claims 1
- IWFLYGRDKJZMBD-UHFFFAOYSA-N n-[3-chloro-5-[(methylsulfonimidoyl)methyl]phenyl]-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=C(Cl)C=2)=N1 IWFLYGRDKJZMBD-UHFFFAOYSA-N 0.000 claims 1
- ORWLRMMKZHWXOJ-UHFFFAOYSA-N n-[4-chloro-3-[(methylsulfonimidoyl)methyl]phenyl]-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C(Cl)=CC=2)=N1 ORWLRMMKZHWXOJ-UHFFFAOYSA-N 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000000369 oxido group Chemical group [*]=O 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Claims (17)
1. Spoj opće formule (I)
[image]
naznačen time da
R1 predstavlja skupinu odabranu iz skupine koju čine C1-C6-alkil-, C3-C7-cikloalkil-, heterociklil-, fenil, heteroaril, fenil-C1-C3-alkil- ili heteroaril-C1-C3-alkil-,
pri čemu je navedena skupina proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine hidroksi, cijano, halogen, halo-C1-C3-alkil-, C1-C6-alkoksi-, C1-C3-fluoroalkoksi-, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini;
R2 predstavlja skupinu odabranu od
[image]
[image]
[image]
R3, R4 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika, atoma fluora, atoma klora, cijano, C1-C3-alkil-, C1-C3-alkoksi-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-;
R5 predstavlja skupinu odabranu od atoma vodika, cijano, -C(O)R9, -C(O)OR9, -S(O)2R9, - C(O)NR10R11, C1-C6-alkil-, C3-C7-cikloalkil-, heterociklila-, fenila, heteroarila
pri čemu je navedena C1-C6-alkil-, C3-C7-cikloalkil-, heterociklil-, fenil ili heteroaril skupina proizvoljno supstituirana s jednim, dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine halogen, cijano, hidroksi, C1-C3-alkil-, C1-C3-alkoksi-, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini , halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-;
R6, R7 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika, atoma fluora, atoma klora, cijano, C1-C3-alkil-, C1-C3-alkoksi-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-;
R8 predstavlja skupinu odabranu od
a) C1-C10-alkil skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, hidroksi, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, cijano, C1-C3-alkil-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-, C1-C3-alkoksi-, C2-C3-alkenil-, C2-C3-alkinil-, C3-C7-cikloalkil-, heterociklil-, fenil, heteroaril,
pri čemu je navedena C3-C7-cikloalkil-, heterociklil-, fenil ili heteroaril skupina proizvoljno supstituirana s jednim, dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine halogen, hidroksi, cijano, C1-C3-alkil-, C1-C3-alkoksi-, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-;
b) C3-C7-cikloalkil- skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine halogen, hidroksi, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, cijano, C1-C3-alkil-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-, C1-C3-alkoksi-, C2-C3-alkenil-, C2-C3-alkinil-;
c) heterociklil- skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, hidroksi, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, cijano, C1-C3-alkil-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-, C1-C3-alkoksi-, C2-C3-alkenil-, C2-C3-alkinil-;
d) fenil skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, hidroksi, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, cijano, C1-C3-alkil-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-, C1-C3-alkoksi-;
e) heteroaril skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, hidroksi, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, cijano, C1-C3-alkil-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-, C1-C3-alkoksi-;
f) fenil-C1-C3-alkil- skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, hidroksi, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, cijano, C1-C3-alkil-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-, C1-C3-alkoksi-;
g) heteroaril-C1-C3-alkil- skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, hidroksi, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, cijano, C1-C3-alkil-, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-, C1-C3-alkoksi-;
R9 predstavlja skupinu odabranu uz skupa koji čine C1-C6-alkil-, C3-C7-cikloalkil-, heterociklil-, fenil, benzil ili heteroaril pri čemu je navedena skupina proizvoljno supstituirana s jednim, dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine halogen, hidroksi, C1-C3-alkil-, C1-C3-alkoksi-, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini , halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-;
R10, R11 predstavljaju, međusobno neovisno, skupinu odabranu od vodika, C1-C6-alkil-, C3-C7-cikloalkil-, heterociklil-, fenil ili heteroaril pri čemu je navedena C1-C6-alkil, C3-C7-cikloalkil-, heterociklil-, fenil ili heteroaril skupina proizvoljno supstituirana s jednim, dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine halogen, hidroksi, C1-C3-alkil-, C1-C3-alkoksi-, amino, alkilamino-, dialkilamino-, acetilamino-, N-metil-N-acetilamino-, ciklički amini, halo-C1-C3-alkil-, C1-C3-fluoroalkoksi-;
ili njegove soli, solvati ili soli solvata.
2. Spoj prema patentnom zahtjevu 1, naznačen time da
R1 predstavlja skupinu odabranu od C1-C6-alkil-, C3-C7-cikloalkil- ili heterociklil-;
R2 predstavlja skupinu odabranu od
[image]
[image]
R3, R4 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika, atoma fluora, atoma klora ili C1-C3-alkil-;
R5 predstavlja skupinu odabranu od atoma vodika, cijano, -C(O)R9, -C(O)OR9, -S(O)2R9, -C(O)NR10R11, C1-C6-alkil-;
R6, R7 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika, atoma fluora, atoma klora;
R8 predstavlja skupinu odabranu od
a) C1-C10-alkil skupine, koja je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, odabrana iz skupine koju čine halogen, hidroksi, C2-C3-alkenil-, C2-C3-alkinil-, C3-C7-cikloalkil-, heterociklil-, fenil, heteroaril,
pri čemu je navedena C3-C7-cikloalkil-, heterociklil-, fenil ili heteroarilna skupina proizvoljno supstituirana s jednim, dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine halogen, cijano, C1-C3-alkil-, halo-C1-C3-alkil-;
b) fenilna skupine;
c) fenil-C1-C3-alkil- skupine, navedena fenilna skupina je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, cijano, C1-C3-alkil-, halo-C1-C3-alkil-;
d) heteroaril-C1-C3-alkil- skupine, navedena heteroarilna skupina je proizvoljno supstituirana s jednim supstituentom odabranim iz skupine koju čini halogen;
R9 predstavlja C1-C6-alkil skupinu;
R10, R11 predstavljaju, međusobno neovisno, skupinu odabranu od vodika ili C1-C6-alkila-;
ili njegove soli, solvati ili soli solvata.
3. Spoj prema patentnom zahtjevu 1 ili 2 s općom formulom (Ia)
[image]
naznačen time da
R1 predstavlja C1-C6-alkil- ili C3-C7-cikloalkil- skupinu;
R2 predstavlja skupinu odabranu od
[image]
R3, R4 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika, atoma fluora, atoma klora, C1-C3-alkil-;
R5 predstavlja skupinu odabranu od atoma vodika, cijano, -C(O)R9, -C(O)OR9, -C(O)NR10R11;
R6, R7 predstavljaju, međusobno neovisno, atom vodika ili atom fluora;
R8 predstavlja skupinu odabranu od
a) C1-C10-alkil skupine, koja je proizvoljno supstituirana s jednim ili dva supstituenta, odabrana iz skupine koju čine hidroksi, C2-C3-alkenil-, C2-C3-alkinil-, C3-C7-cikloalkil-, fenil, heteroaril, pri čemu je navedena C3-C7-cikloalkil-, fenil ili heteroaril skupina proizvoljno supstituirana s jednim, dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine halogen, cijano, halo-C1-C3-alkil-;
b) fenil-C1-C3-alkil- skupine, koja fenilna skupina je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine halogen, cijano, halo-C1-C3-alkil-;
c) heteroaril-C1-C3-alkil- skupine, navedena heteroarilna skupina je proizvoljno supstituirana s jednim supstituentom odabranim iz skupine koja sadrži halogen;
R9 predstavlja C1-C6-alkil skupinu;
R10, R11 predstavljaju, međusobno neovisno, skupinu odabranu od vodika, C1-C6-alkila-;
ili njegove soli, solvati ili soli solvata.
4. Spoj prema patentnom zahtjevu 1, 2 ili 3 s općom formulom (Ia)
[image]
naznačen time da
R1 predstavlja skupinu odabranu od metila;
R2 predstavlja skupinu odabranu od 4-fluoro-2-metoksifenil-, 2-(benziloksi)-4-fluorofenil-, 4,5-difluoro-2-metoksifenil-, 2-[(4-fluorobenzil)oksi]fenil-, 4-fluoro-2-[(4-fluorobenzil)oksi]fenil;
R3 predstavlja skupinu odabranu od atoma vodika, atoma fluora, atoma klora;
R4 predstavlja skupinu odabranu od atoma vodika, atoma klora;
R5 predstavlja skupinu odabranu od atoma vodika, -C(O)R9, -C(O)OR9;
R9 predstavlja skupinu odabranu od metila ili etila;
ili njegove soli, solvati ili soli solvata.
5. Spoj prema patentnom zahtjevu 1, 2, 3 ili 4 s općom formulom (Ia)
[image]
naznačen time da
R1 predstavlja skupinu odabranu od metila;
R2 predstavlja skupinu odabranu od 4-fluoro-2-metoksifenil- ili 4,5-difluoro-2-metoksifenil-;
R3, R4 predstavljaju, međusobno neovisno, atom vodika;
R5 predstavlja atom vodika;
ili njegove soli, solvati ili soli solvata.
6. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time da
R1 predstavlja skupinu odabranu od metila, etila, ciklopropila, tetrahidro-2H-piranila-;
R2 predstavlja skupinu odabranu od
[image]
[image]
R3, R4 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika, atoma fluora, atoma klora ili metila;
R5 predstavlja skupinu odabranu od atoma vodika, cijano, -C(O)R9, -C(O)OR9, -S(O)2R9, -C(O)NR10R11 ili C1-C6-alkil-;
R6, R7 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika, atoma fluora, atoma klora;
R8 predstavlja skupinu odabranu od
a) metil, etil propil ili butil skupine, koja skupina je proizvoljno supstituirana s jednim ili dva ili tri supstituenta, odabrana iz skupine koju čine halogen, hidroksi, etenil, propenil, etinil-, propinil-, ciklopentil-, cikloheksil, tetrahidro-2H-piranil-, fenil, piridinil-, tiazolil-, oksazolil, pri čemu je navedena fenil ili piridinil- skupina proizvoljno supstituirana s jednim, dva ili tri supstituenta, ista ili različita, odabrana iz skupa koji čine fluoro ili atom klora, cijano, metil, ili trifluorometil;
b) (2H2)metil skupine supstituirane s (2H5)fenil skupinom;
c) fenil skupine;
d) benzil skupine, koji fenilni prsten je proizvoljno supstituiran s jednim ili dva ili tri supstituenta, ista ili različita, odabrana iz skupine koju čine atom fluora, atom klora, cijano, metil ili trifluorometil-;
e) piridin-2-ilmetil- skupine, koji piridin je proizvoljno supstituiran s jednim atomom fluora;
f) piridin-3-ilmetil- skupine, koji piridin je proizvoljno supstituiran s jednim atomom fluora;
g) piridin-4-ilmetil- skupine, koji piridin je proizvoljno supstituiran s jednim atomom fluora;
h) tiazolilmetil- skupine;
i) oksazolilmetil- skupine
R9 predstavlja metil ili etil skupinu;
R10, R11 predstavljaju, međusobno neovisno, skupinu odabranu od vodika, metila;
ili njegove soli, solvati ili soli solvata.
7. Spoj prema bilo kojem od zahtjeva 1, 2 ili 3, naznačen time da
R1 predstavlja metil ili etil ili ciklopropil skupinu;
R2 predstavlja skupinu odabranu od
[image]
R3 predstavlja skupinu odabranu od atoma vodika, atoma fluora, atoma klora ili metila;
R4 predstavlja skupinu odabranu od atoma vodika ili atoma fluora
R5 predstavlja skupinu odabranu od atoma vodika, cijano, -C(O)R9, -C(O)OR9, -C(O)NR10R11;
R6, R7 predstavljaju, međusobno neovisno, skupinu odabranu od atoma vodika ili atoma fluora;
R8 predstavlja skupinu odabranu od
metil, etil, prop-2-en-1-il-, 2-metilprop-2-en-1il-, 2-(hidroksimetil)prop-2-en-1-il-, (2Z)-but-2-en-1-il-, prop-2-in-lil-, but-2-in-lil-, cikloheksilmetil-, benzil-, 3-cijanobenzil-, 3-fluorobenzil-, 3-klorobenzil-, 4-fluorobenzil-,4-klorobenzil-, 3-fluoro-5-(trifluorometil)benzil-, 3-kloro-5-fluorobenzil-, piridin-4-il-, 2-fluoropiridin-4-il-, 2,3,5-trifluorobenzil-, 3,4,5-trifluorobenzil-,
R9 predstavlja metil ili etil skupinu;
R10, R11 predstavljaju, međusobno neovisno, skupinu odabranu od vodika, C1-C6-alkila-;
ili njegove soli, solvati ili soli solvata.
8. Spoj prema patentnom zahtjevu 1, naznačen time da je odabran iz skupa koji čine
(rac)-etil [(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(4-fluoro-2-metoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-(4-fluoro-2-metoksifenil)-N-3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-(4-fluoro-2-metoksifenil)-N-3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-etil {[3-({4-[2-(benziloksi)-4-fluorofenil]-1,3,5-triazin-2-il}amino)benzil](metil)oksido-λ6-sulfaniliden} karbamat,
(rac)-4-[2-(benziloksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-[2-(benziloksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-[2-(benziloksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-etil [(3-{[4-(4,5-difluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(4,5-difluoro-2-metoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-etil [(3-{[4-(4-kloro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac) 4-(4-kloro-2-metoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil;-1,3,5-triazin-2-amin,
4-(4-kloro-2-metoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-(4-kloro-2-metoksifenil)-N-3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-1-[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]-3-metilurea,
1-[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]-3-metilurea; enantiomer 1,
1-[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]-3-metilurea; enantiomer 2,
(rac)-etil [(3-{[4-(2,2-difluoro-1,3-benzodioksol-4-il)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden] karbamat,
(rac)-4-(2,2-difluoro-1,3-benzodioksol-4-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-etil [(3-{[4-(5-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(5-fluoro-2-metoksifenil)-N-3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-(5-fluoro-2-metoksifenil)-N-3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-(5-fluoro-2-metoksifenil)-N-3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-N-[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]acetamid,
(rac)-etil [(3-{[4-(2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(2-metoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-(2-metoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-(2-metoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-etil [(3-{[4-(3,4-dihidro-2H-kromen-8-il)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(3,4-dihidro-2H-kromen-8-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-(3,4-dihidro-2H-kromen-8-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-(3,4-dihidro-2H-kromen-8-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-etil [(3-{[4-(2,3-dihidro-1-benzofuran-7-il)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(2,3-dihidro-1-benzofuran-7-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-(2,3-dihidro-1-benzofuran-7-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-(2,3-dihidro-1-benzofuran-7-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-etil [(3-{[4-(2,3-dihidro-1,4-benzodioksin-5-il)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(2,3-dihidro-1,4-benzodioksin-5-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-(2,3-dihidro-1,4-benzodioksin-5-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-(2,3-dihidro-1,4-benzodioksin-5-il)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-N-{3-[(N,S-Dimetilsulfonimidoil)metil]fenil}-4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-amin,
(rac)-etil [{3-[(4-{2-[(4-fluorobenzil)oksi]fenil}-1,3,5-triazin-2-il)amino]benzil}(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-{2-[(4-fluorobenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-N-[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]metanesulfonamid,
(rac)-etil [(3-{[4-(3-kloro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-etil {[3-({4-[5-fluoro-2-(tetrahidro-2H-piran-4-ilmetoksi)fenil]-1,3,5-triazin-2-il}amino)benzil](metil)oksido-λ6-sulfaniliden}karbamat,
(rac)-etil [metil(oksido)(3-{[4-(2-fenoksifenil)-1,3,5-triazin-2-il]amino}benzil)-λ6-sulfaniliden]karbamat,
(rac)-[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden] cijanamid,
[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden] cijanamid; enantiomer 1,
[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]cijanamid; enantiomer 2,
(rac)-etil [(3-fluoro-5-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)-oksido-λ6-sulfaniliden]karbamat,
(rac)-4-(4-fluoro-2-metoksifenil)-N-{3-fluoro-5-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-(4-fluoro-2-metoksifenil)-N-{3-fluoro-5-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin, enantiomer 1,
4-(4-fluoro-2-metoksifenil)-N-{3-fluoro-5-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin, enantiomer 2,
(rac)-4-[2-(cikloheksilmetoksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[(4-fluorobenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[2-(tetrahidro-2H-piran-4-il)etoksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-(4-fluoro-2-metoksifenil)-N-(3-{[S-(tetrahidro-2H-piran-4-il)sulfonimidoil]metil}fenil)-1,3,5-triazin-2-amin,
(rac)-N-{4-kloro-3-[(S-metilsulfonimidoil)metil]fenil}-4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-amin,
(rac)-etil [{3-[(4-{2-[(3,4-diklorobenzil)oksi]fenil}-1,3,5-triazin-2-il)amino]benzil}(metil)oksido-λ6-sulfaniliden]karbamat,
(rac)-4-{2-[(3,4-diklorobenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-(4-fluoro-2-{[(2H5)fenil(2H2)metil]oksi}fenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-[2-(1-ciklopentiletoksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-N-{3-kloro-5-[(S-metilsulfonimidoil)metil]fenil}-4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(3,3,3-trifluoropropoksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(piridin-3-ilmetoksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(piridin-2-ilmetoksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(piridin-4-ilmetoksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-{4-fluoro-2-[1-(4-fluorofenil)etoksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin, smjesa 4 stereoizomera,
(rac)-[(3-fluoro-5-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil-λ6-sulfaniliden]cijanamid,
[(3-fluoro-5-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil-λ6-sulfaniliden]cijanamid; enantiomer 1,
[(3-fluoro-5-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil-λ6-sulfaniliden]cijanamid; enantiomer 2,
(rac)-4-[2-(but-2-in-1-iloksi)-4-fluorofenil]-N-3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-[2-(but-2-in-1-iloksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-[2-(but-2-in-1-iloksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-4-[2-(2-ciklopropiletoksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(prop-2-in-1-iloksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-[4-fluoro-2-(prop-2-in-1-iloksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-[4-fluoro-2-(prop-2-in-1-iloksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-4-{2-[(3,4-difluorobenzil)oksi]-4-fluorofenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(1,3-tiazol-5-ilmetoksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[(2-fluoropiridin-4-il)metoksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
4-{4-fluoro-2-[(2-fluoropiridin-4-il)metoksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 1,
4-{4-fluoro-2-[(2-fluoropiridin-4-il)metoksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin; enantiomer 2,
(rac)-4-[4-fluoro-2-(prop-2-en-1-iloksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-(4-fluoro-2-{[4-(trifluorometil)benzil]oksi}fenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{2-[(4-klorobenzil)oksi]-4-fluorofenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-(2-etoksi-4-fluorofenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-(4-fluoro-2-{[3-fluoro-5-(trifluorometil)benzil]oksi}fenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[(3-fluorobenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-(4-fluoro-2-propoksifenil)-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{2-[(3-klorobenzil)oksi]-4-fluorofenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(1,2-oksazol-3-ilmetoksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{2-[(3-kloro-5-fluorobenzil)oksi]-4-fluorofenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[2-(2,2-difluoroetoksi)-4-fluorofenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[(4-fluoro-3-metilbenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{2-[(3-kloro-4-fluorobenzil)oksi]-4-fluorofenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-3-({5-fluoro-2-[4-({3-[(S-metilsulfonimidoil)metil]fenil}amino)-1,3,5-triazin-2-il]fenoksi} metil)benzonitril,
(rac)-4-{4-fluoro-2-[(2-metilprop-2-en-1-il)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-[4-fluoro-2-(4,4,4-trifluorobutoksi)fenil]-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[(2,3,5-trifluorobenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{2-[(2Z)-but-2-en-1-iloksi]-4-fluorofenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[(2,4,5-trifluorobenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-4-{4-fluoro-2-[(3,4,5-trifluorobenzil)oksi]fenil}-N-{3-[(S-metilsulfonimidoil)metil]fenil}-1,3,5-triazin-2-amin,
(rac)-[(2,3-difluoro-5-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)(metil)oksido-λ6-sulfaniliden]cijanamid,
(rac)-N-{3,4-difluoro-5-[(S-metilsulfonimidoil)metil]fenil}-4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-amin,
(rac)-[etil(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)oksido-λ6-sulfaniliden]cijanamid,
(rac)-N-{3-[(S-etilsulfonimidoil)metil]fenil}-4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-amin
N-{3-[(S-etilsulfonimidoil)metil]fenil}-4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-amin; enantiomer 1,
N-{3-[(S-etilsulfonimidoil)metil]fenil}-4-(4-fluoro-2-metoksifenil)-l,3,5-triazin-2-amin; enantiomer 2,
(rac)-[(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}-5-metilbenzil)(metil)oksido-λ6-sulfaniliden] cijanamid,
(rac)-2-({5-fluoro-2-[4-({3-[(S-metilsulfonimidoil)metil]fenil}amino)-1,3,5-triazin-2-il]fenoksi}metil)prop-2-en-1-ol,
(rac)-[ciklopropil(3-{[4-(4-fluoro-2-metoksifenil)-1,3,5-triazin-2-il]amino}benzil)oksido-λ6-sulfaniliden] cijanamid,
ili njegove soli, solvati ili soli solvata.
9. Spoj opće formule (I) ili (Ia) prema bilo kojem od zahtjeva 1 do 8 naznačen time da je za uporabu za liječenje i/ili sprječavanje hiper-proliferativnih poremećaja, virusno izazvanih infektivnih bolesti i/ili kardiovaskularnih bolesti.
10. Farmaceutska kombinacija naznačena time da sadrži spoj prema bilo kojem od zahtjeva 1 do 8 u kombinaciji s barem jednim ili više dodatnih aktivnih sastojaka.
11. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 8 u kombinaciji s inertnim, netoksičnim, farmaceutski prikladnim pomoćnim sredstvom.
12. Farmaceutska kombinacija prema zahtjevu 10 naznačen time da je za uporabu za liječenje i/ili sprječavanje hiper-proliferativnih poremećaja, virusno izazvanih infektivnih bolesti i/ili kardiovaskularnih bolesti.
13. Farmaceutski pripravak prema zahtjevu 11 naznačen time da je za uporabu za liječenje i/ili sprječavanje hiper-proliferativnih poremećaja, virusno izazvanih infektivnih bolesti i/ili kardiovaskularnih bolesti.
14. Spoj opće formule (3)
[image]
naznačen time da
R1, R3 i R4 su kako je definirano za spoj s općom formulom (I) ili (Ia) prema bilo kojem od zahtjeva 1 do 7.
15. Spoj opće formule (2)
[image]
naznačen time da
R1, R3 i R4 su kako je definirano za spoj s općom formulom (I) ili (Ia) prema bilo kojem od zahtjeva 1 do 7.
16. Spoj opće formule (11)
[image]
naznačen time da
R1, R3 i R4 su kako je definirano za spoj s općom formulom (I) ili (Ia) prema bilo kojem od zahtjeva 1 do 7.
17. Spoj opće formule (12)
[image]
naznačen time da
R1, R3 i R4 su kako je definirano za spoj s općom formulom (I) ili (Ia) prema bilo kojem od zahtjeva 1 do 7.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11167317A EP2527332A1 (en) | 2011-05-24 | 2011-05-24 | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
EP11180759 | 2011-09-09 | ||
EP12158030 | 2012-03-05 | ||
EP12721558.0A EP2714654B1 (en) | 2011-05-24 | 2012-05-21 | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group |
PCT/EP2012/059399 WO2012160034A1 (en) | 2011-05-24 | 2012-05-21 | 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20151060T1 true HRP20151060T1 (hr) | 2015-11-06 |
Family
ID=46085997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20151060TT HRP20151060T1 (hr) | 2011-05-24 | 2015-10-06 | 4-aril-n-fenil-1,3,5-triazin-2-amini koji sadrže sulfoksimin skupinu |
Country Status (41)
Country | Link |
---|---|
US (2) | US9669034B2 (hr) |
EP (1) | EP2714654B1 (hr) |
JP (1) | JP5955948B2 (hr) |
KR (1) | KR101958501B1 (hr) |
CN (1) | CN103702979B (hr) |
AP (1) | AP3884A (hr) |
AR (1) | AR086552A1 (hr) |
AU (1) | AU2012260983B2 (hr) |
BR (1) | BR112013029976A2 (hr) |
CA (1) | CA2837027C (hr) |
CL (1) | CL2013003360A1 (hr) |
CO (1) | CO6811860A2 (hr) |
CR (1) | CR20130620A (hr) |
CU (1) | CU24175B1 (hr) |
CY (1) | CY1116791T1 (hr) |
DK (1) | DK2714654T3 (hr) |
DO (1) | DOP2013000277A (hr) |
EA (1) | EA023418B1 (hr) |
EC (1) | ECSP13013040A (hr) |
ES (1) | ES2549529T3 (hr) |
GT (1) | GT201300293A (hr) |
HR (1) | HRP20151060T1 (hr) |
HU (1) | HUE027853T2 (hr) |
IL (1) | IL229314A (hr) |
JO (1) | JO3204B1 (hr) |
MA (1) | MA35132B1 (hr) |
ME (1) | ME02227B (hr) |
MX (1) | MX340803B (hr) |
MY (1) | MY165748A (hr) |
PE (1) | PE20141075A1 (hr) |
PL (1) | PL2714654T3 (hr) |
PT (1) | PT2714654E (hr) |
RS (1) | RS54264B1 (hr) |
SG (2) | SG10201606952XA (hr) |
SI (1) | SI2714654T1 (hr) |
TN (1) | TN2013000485A1 (hr) |
TW (2) | TWI555737B (hr) |
UA (1) | UA112870C2 (hr) |
UY (1) | UY34095A (hr) |
WO (1) | WO2012160034A1 (hr) |
ZA (1) | ZA201309672B (hr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2740424T3 (es) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
SG10201403696UA (en) | 2009-06-29 | 2014-10-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
TR201809699T4 (tr) | 2011-05-03 | 2018-07-23 | Agios Pharmaceuticals Inc | Tedavi̇de kullanilmaya yöneli̇k pi̇ruvat ki̇naz akti̇vatörleri̇. |
TWI555737B (zh) * | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
WO2013037894A1 (en) * | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
SG10201602862RA (en) | 2012-01-06 | 2016-05-30 | Agios Pharmaceuticals Inc | Therapeutically Active Compounds And Their Methods Of Use |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
MX365747B (es) | 2012-10-15 | 2019-06-12 | Agios Pharmaceuticals Inc | Compuestos derivados de diarilurea de sulfonamida de arilo y sus usos. |
WO2015001021A1 (en) * | 2013-07-04 | 2015-01-08 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015006591A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
MX2016000336A (es) | 2013-07-11 | 2016-08-08 | Agios Pharmaceuticals Inc | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer. |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
CA2942119A1 (en) * | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
KR102400737B1 (ko) | 2014-03-14 | 2022-05-20 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
WO2016113187A1 (en) * | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating leukemias |
WO2016150902A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers |
CA2980507A1 (en) | 2015-03-24 | 2016-09-29 | Public University Corporation Nagoya City University | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas |
JP2018509439A (ja) * | 2015-03-24 | 2018-04-05 | バイエル ファーマ アクチエンゲゼルシャフト | 多発性骨髄腫を治療するための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用 |
JP6738352B2 (ja) | 2015-05-08 | 2020-08-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体 |
EP3307271B1 (en) | 2015-06-11 | 2023-09-13 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
AU2016338557B2 (en) | 2015-10-15 | 2022-05-26 | Celgene Corporation | Combination therapy for treating malignancies |
EP3362065B1 (en) | 2015-10-15 | 2024-04-03 | Les Laboratoires Servier | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
KR102354411B1 (ko) | 2016-04-06 | 2022-01-21 | 이노베이티브 몰리큘스 게엠베하 | 항바이러스제로서 유용한 아미노티아졸 유도체 |
EP3585774B1 (en) | 2017-02-24 | 2021-11-10 | Merck Sharp & Dohme Corp. | Novel substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
PT3692039T (pt) | 2017-10-05 | 2023-03-07 | Innovative Molecules Gmbh | Enantiómeros de tiazóis substituídos como compostos antivirais |
EA202091894A1 (ru) | 2018-02-13 | 2020-12-28 | Байер Акциенгезельшафт | Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
EP4129293A4 (en) * | 2020-03-27 | 2024-04-03 | Univ Kyoto | INHIBITOR OF NERVE CELL DEGENERATION |
EP4174077A1 (en) * | 2021-10-27 | 2023-05-03 | Merck Patent GmbH | Electronic switching device |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1030660A (en) | 1912-06-25 | Henry C Hunt | Tool for removing floors, siding, scaffolds, &c. | |
GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
DE60039059D1 (de) | 1999-10-07 | 2008-07-10 | Amgen Inc | Triazin-kinase-hemmer |
PL214667B1 (pl) | 2000-12-21 | 2013-08-30 | Glaxo Group Ltd | Pochodne pirydynoaminy, srodek farmaceutyczny i zastosowanie pochodnych pirymidynoaminy do wytwarzania leku |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
WO2003037346A1 (en) | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
EP1546121B1 (en) | 2002-07-18 | 2012-08-29 | Janssen Pharmaceutica NV | Substituted triazine kinase inhibitors |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
AU2004212421B2 (en) | 2003-02-07 | 2009-08-20 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
WO2007023507A2 (en) | 2005-06-20 | 2007-03-01 | Wockhardt Limited | Oxazolidinones bearing antimicrobial activity composition and methods of preparation |
DE102005062742A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
TW201309635A (zh) | 2006-02-10 | 2013-03-01 | Dow Agrosciences Llc | 殺蟲性之n-取代(6-鹵烷基吡啶-3-基)烷基磺醯亞胺(二) |
JP4305477B2 (ja) | 2006-07-25 | 2009-07-29 | トヨタ自動車株式会社 | 火花点火式内燃機関 |
DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
WO2008079918A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
EP2094682A2 (en) * | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
JP5379787B2 (ja) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
WO2008129070A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
JP5276660B2 (ja) | 2007-07-20 | 2013-08-28 | ダウ アグロサイエンシィズ エルエルシー | 植物の成長力の増大 |
JP5611826B2 (ja) | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
EP2179991A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
KR20120114224A (ko) | 2009-10-12 | 2012-10-16 | 마이렉시스 인코포레이티드 | Ikk 엡실론 및/또는 tbk1의 억제제로서의 아미노-피리미딘 화합물 |
CA2789200C (en) | 2010-03-22 | 2020-05-26 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
US9242937B2 (en) | 2011-03-02 | 2016-01-26 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted pyridine derivatives |
CN103582482B (zh) | 2011-03-02 | 2016-10-12 | 利德探索中心有限公司 | 药学活性的二取代的三嗪衍生物 |
CN103476759B (zh) * | 2011-04-19 | 2016-03-16 | 拜耳知识产权有限责任公司 | 取代的4-芳基-n-苯基-1,3,5-三嗪-2-胺 |
TWI555737B (zh) * | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
CN103917527B (zh) | 2011-09-16 | 2017-05-31 | 拜耳知识产权有限责任公司 | 二取代的5‑氟‑嘧啶 |
WO2013037894A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
CN105283453B (zh) | 2012-10-18 | 2018-06-22 | 拜耳药业股份公司 | 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物 |
ES2597232T3 (es) | 2012-10-18 | 2017-01-17 | Bayer Pharma Aktiengesellschaft | 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona |
CN104854091B (zh) | 2012-10-18 | 2018-04-03 | 拜耳药业股份公司 | 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
CN104918918B (zh) | 2012-11-15 | 2017-10-24 | 拜耳药业股份公司 | 含磺亚胺基团的4‑(邻)‑氟苯基‑5‑氟嘧啶‑2‑基胺 |
US9650340B2 (en) | 2012-11-15 | 2017-05-16 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
WO2015001021A1 (en) | 2013-07-04 | 2015-01-08 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
CA2942119A1 (en) | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
-
2012
- 2012-05-18 TW TW101117904A patent/TWI555737B/zh not_active IP Right Cessation
- 2012-05-18 TW TW105122136A patent/TW201636330A/zh unknown
- 2012-05-21 PL PL12721558T patent/PL2714654T3/pl unknown
- 2012-05-21 EP EP12721558.0A patent/EP2714654B1/en active Active
- 2012-05-21 CN CN201280036561.6A patent/CN103702979B/zh active Active
- 2012-05-21 SG SG10201606952XA patent/SG10201606952XA/en unknown
- 2012-05-21 PT PT127215580T patent/PT2714654E/pt unknown
- 2012-05-21 US US14/122,063 patent/US9669034B2/en active Active
- 2012-05-21 SI SI201230330T patent/SI2714654T1/sl unknown
- 2012-05-21 CU CUP2013000157A patent/CU24175B1/es active IP Right Grant
- 2012-05-21 ME MEP-2015-168A patent/ME02227B/me unknown
- 2012-05-21 MX MX2013013711A patent/MX340803B/es active IP Right Grant
- 2012-05-21 HU HUE12721558A patent/HUE027853T2/en unknown
- 2012-05-21 SG SG2013082870A patent/SG194856A1/en unknown
- 2012-05-21 KR KR1020137033871A patent/KR101958501B1/ko active IP Right Grant
- 2012-05-21 DK DK12721558.0T patent/DK2714654T3/en active
- 2012-05-21 WO PCT/EP2012/059399 patent/WO2012160034A1/en active Application Filing
- 2012-05-21 MY MYPI2013702220A patent/MY165748A/en unknown
- 2012-05-21 RS RS20150640A patent/RS54264B1/en unknown
- 2012-05-21 UA UAA201314969A patent/UA112870C2/uk unknown
- 2012-05-21 ES ES12721558.0T patent/ES2549529T3/es active Active
- 2012-05-21 AU AU2012260983A patent/AU2012260983B2/en active Active
- 2012-05-21 BR BR112013029976A patent/BR112013029976A2/pt not_active Application Discontinuation
- 2012-05-21 CA CA2837027A patent/CA2837027C/en active Active
- 2012-05-21 EA EA201301320A patent/EA023418B1/ru not_active IP Right Cessation
- 2012-05-21 AP AP2013007254A patent/AP3884A/en active
- 2012-05-21 JP JP2014511836A patent/JP5955948B2/ja not_active Expired - Fee Related
- 2012-05-21 PE PE2013002560A patent/PE20141075A1/es not_active Application Discontinuation
- 2012-05-23 JO JOP/2012/0122A patent/JO3204B1/ar active
- 2012-05-24 AR ARP120101840A patent/AR086552A1/es active Pending
- 2012-05-24 UY UY0001034095A patent/UY34095A/es not_active Application Discontinuation
-
2013
- 2013-11-07 IL IL229314A patent/IL229314A/en active IP Right Grant
- 2013-11-22 MA MA36460A patent/MA35132B1/fr unknown
- 2013-11-22 TN TNP2013000485A patent/TN2013000485A1/fr unknown
- 2013-11-22 GT GT201300293A patent/GT201300293A/es unknown
- 2013-11-22 CO CO13275593A patent/CO6811860A2/es active IP Right Grant
- 2013-11-22 EC ECSP13013040 patent/ECSP13013040A/es unknown
- 2013-11-22 DO DO2013000277A patent/DOP2013000277A/es unknown
- 2013-11-22 CL CL2013003360A patent/CL2013003360A1/es unknown
- 2013-11-25 CR CR20130620A patent/CR20130620A/es unknown
- 2013-12-20 ZA ZA2013/09672A patent/ZA201309672B/en unknown
-
2015
- 2015-10-06 HR HRP20151060TT patent/HRP20151060T1/hr unknown
- 2015-10-08 CY CY20151100912T patent/CY1116791T1/el unknown
-
2017
- 2017-04-14 US US15/488,155 patent/US9962389B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20151060T1 (hr) | 4-aril-n-fenil-1,3,5-triazin-2-amini koji sadrže sulfoksimin skupinu | |
RU2013151118A (ru) | Замещенные 4-арил-n-фенил-1,3,5-триазин-2-амины | |
RU2326869C2 (ru) | Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения | |
RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
RU2423349C2 (ru) | Гетероциклические соединения в качестве антагонистов ccr2b | |
JP2016528201A5 (hr) | ||
RU2423354C2 (ru) | Соединения и композиции - модуляторы сигнального пути hedgehog | |
JP2018522823A5 (hr) | ||
JP2005514334A5 (hr) | ||
HRP20130220T1 (hr) | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih | |
RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
HRP20180971T1 (hr) | Inhibitori indolamin 2,3-dioksigenaze (ido) | |
JP2017530199A5 (hr) | ||
AR065814A1 (es) | Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados. | |
FI3883936T3 (fi) | Uusia heterosyklisiä yhdisteitä | |
RU2004129780A (ru) | Производные аминоиндазолов, способ получения и промежуточные продукты этого способа в качестве лекарственных средств и содержащие их фармацевтические композиции | |
AR109007A2 (es) | Compuesto de oxazol y composición farmacéutica | |
WO2010131922A4 (en) | Amide compound, preparation method thereof and pharmaceutical composition comprising same | |
RU2007141346A (ru) | Диарилсульфонсульфонамиды и их применение | |
RU2006145205A (ru) | Терапевтические соединения: пиридин в качестве каркаса | |
JP2020522520A5 (hr) | ||
RU2005136655A (ru) | Производные пиримидина, пригодные для лечения болезней, опосредованных сrth2 | |
JP2005511543A5 (hr) | ||
HRP20141190T1 (hr) | Disupstituirani derivati piridina kao antikancerogena sredstva | |
JP2012526803A5 (hr) |